These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28982867)

  • 1. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
    Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM
    Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
    Giordano G; Pancione M; Olivieri N; Parcesepe P; Velocci M; Di Raimo T; Coppola L; Toffoli G; D'Andrea MR
    World J Gastroenterol; 2017 Aug; 23(32):5875-5886. PubMed ID: 28932079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.
    Jin F; Zhu H; Shi F; Kong L; Yu J
    Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
    Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
    Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.
    Aigner J; Marmé F; Smetanay K; Schuetz F; Jaeger D; Schneeweiss A
    Anticancer Res; 2013 Aug; 33(8):3407-13. PubMed ID: 23898112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
    Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
    Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis.
    Jeon CY; Pandol SJ; Wu B; Cook-Wiens G; Gottlieb RA; Merz CN; Goodman MT
    PLoS One; 2015; 10(4):e0121783. PubMed ID: 25830309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.
    Langer CJ; Hirsh V; Okamoto I; Lin FJ; Wan Y; Whiting S; Ong TJ; Renschler MF; Botteman MF
    Br J Cancer; 2015 Jun; 113(1):20-9. PubMed ID: 26035702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer.
    Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
    Anticancer Res; 2016 Dec; 36(12):6699-6703. PubMed ID: 27920005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer.
    Wu BU; Chang J; Jeon CY; Pandol SJ; Huang B; Ngor EW; Difronzo AL; Cooper RM
    Am J Gastroenterol; 2015 Aug; 110(8):1233-9. PubMed ID: 26195180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.
    Ko YJ; Canil CM; Mukherjee SD; Winquist E; Elser C; Eisen A; Reaume MN; Zhang L; Sridhar SS
    Lancet Oncol; 2013 Jul; 14(8):769-76. PubMed ID: 23706985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion: A case report in a patient with metastatic pancreatic adenocarcinoma.
    Neuzillet C; Babai S; Kempf E; Pujol G; Rousseau B; Le-Louët H; Christophe Tournigand
    Medicine (Baltimore); 2016 Jun; 95(26):e4006. PubMed ID: 27368013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study.
    Chen Q; Ning Z; Wang L; Ying H; Dong S; Zhang C; Shen X; Guo Y; Chen H; Zhu X; Shen Y; Shi W; Hua Y; Wang K; Lin J; Xu L; Chen L; Feng L; Zhang X; Xie J; Sun B; Sun Y; Gu W; Kang M; Tang Z; Chen Z; Chen Z; Liu L; Yu J; Li Z; Meng Z
    Oncotarget; 2016 Dec; 7(51):85603-85612. PubMed ID: 27811354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
    Awasthi N; Scire E; Monahan S; Grojean M; Zhang E; Schwarz MA; Schwarz RE
    Oncotarget; 2016 Jul; 7(30):46988-47001. PubMed ID: 27127884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.
    Johnston WC; Hoen HM; Cassera MA; Newell PH; Hammill CW; Hansen PD; Wolf RF
    HPB (Oxford); 2016 Jan; 18(1):21-8. PubMed ID: 26776847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
    Bang YJ; Im SA; Lee KW; Cho JY; Song EK; Lee KH; Kim YH; Park JO; Chun HG; Zang DY; Fielding A; Rowbottom J; Hodgson D; O'Connor MJ; Yin X; Kim WH
    J Clin Oncol; 2015 Nov; 33(33):3858-65. PubMed ID: 26282658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer.
    Kozak MM; Anderson EM; von Eyben R; Pai JS; Poultsides GA; Visser BC; Norton JA; Koong AC; Chang DT
    Pancreas; 2016 Jan; 45(1):64-70. PubMed ID: 26474429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
    Dranitsaris G; Coleman R; Gradishar W
    Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.